Analysis of Genomic DNA Alterations in Familial Schizophrenia
Persons with schizophrenia experience imaginary voices, visions and disorganized thoughts, and are handicapped when it comes to social life, which is detrimental to the affected individuals and the community. Although the pathogenesis of this mental disease has not been clearly elucidated, much evidence suggests that inheritance is of major etiological importance and multiple genetic components are implicated. Previous linkage studies of familial schizophrenia have led to the successful identification of numerous susceptibility loci covering many of the human chromosomes, including chromosome 1q, 5q, 6p22, 6p24, 8q21, 13q32, 15q13-14 and 22q11, etc. Necessities for further identification of candidate genes involved in familial schizophrenia by taking a genome-wide approach are listed as follows:
1. given that multiple genes are responsible for this disease, it is of critical interest to view the complete molecular profiling of schizophrenia's genome;
2. identification of promising schizophrenia candidate genes by genome-wide scanning will facilitate the development of molecular markers and provide a more objective and effective assessment method in psychotic diagnosis and prognosis;
3. prevention of the onset of this disorder will be improved by early classification of individuals bearing strong genetic loading for schizophrenia as a high risk population;
4. making a breakthrough into the investigation of schizophrenia pathogenesis by the characterization of susceptible genes found by genome-wide exploring.
Array-based comparative genomic hybridization (CGH) allows high-throughput genome-wide survey for DNA copy number aberrations, providing a powerful tool for investigating genetic disorders and for developing diagnostic and therapeutic targets. Arrays used in this study consist of approximately 43,000 60-mer oligonucleotide probes that span coding and noncoding regions of the whole human genome with an average spatial resolution of around 35 kb. Furthermore, the sensitivity of these arrays is capable of detecting and mapping regions of single-copy losses, homozygous deletions, and amplicons of various sizes even when using full-complexity genomic samples. In this study, the investigators will conduct an array-based comparative genomic hybridization (CGH) with genomic DNA of many affected members from "schizophrenia families" (the investigators classified families according to the presence or absence of two or more affected members) to identify a set of candidate genes associated with this disease. It is hoped that the results obtained from this study will improve the accuracy and efficiency of psychotic treatment.
Additional Descriptors: Psychosocial, Observational Model: Defined Population, Time Perspective: Longitudinal, Time Perspective: Retrospective/Prospective
National Taiwan University Hospital
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT00166738
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination.
A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.
An obsolete concept, historically used for childhood mental disorders thought to be a form of schizophrenia.
A type of schizophrenia characterized by frequent incoherence; marked loosening of associations, or grossly disorganized behavior and flat or grossly inappropriate affect that does not meet the criteria for the catatonic type; associated features include extreme social withdrawal, grimacing, mannerisms, mirror gazing, inappropriate giggling, and other odd behavior. (Dorland, 27th ed)
A benzocycloheptapyridoisoquinolinol that has been used as an antipsychotic, especially in schizophrenia.
This study will create a DNA collection with blood samples from families with at least two siblings who have schizophrenia symptoms. This collection will help scientists identify genes tha...
Schizophrenia has long been known to be an illness with significant evidence for a genetic predisposition. The purpose of this study is to determine the genetic abnormalities that cause c...
The proposed study would evaluate the benefits of riluzole add-on treatment to patients with schizophrenia who are already receiving medications, but still experience symptoms. Neuroprotec...
The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects wi...
This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatme...
Empirical evidence continues to suggest a biologically distinct violent subtype of schizophrenia. The present study examined whether murderers with schizophrenia would demonstrate resting EEG deficits...
Background: In the 20th century, catatonia was usually deemed a subtype of schizophrenia. Recently, the nature and classification of catatonia are being reconsidered. This study is the first to descri...
How will we view schizophrenia in 2030? Schizophrenia today is a chronic, frequently disabling mental disorder that affects about one per cent of the world's population. After a century of studying sc...
The evidence regarding the association between schizophrenia and the fractions of bilirubin is mixed. In a retrospective case-control design we examined the association between total bilirubin, conjug...
The gene encoding d-amino acid oxidase (DAO), which acts as a receptor for the schizophrenia-associated neurotransmitter, N-methyl-D-aspartate (NMDA), is regarded as a potential candidate gene for sch...